About AGTC

AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases in ophthalmology. AGTC's lead product candidates focus on X-linked retinoschisis, achromatopsia and X-linked retinitis pigmentosa, which are inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments. AGTC is also pursuing pre-clinical development of treatments for wet AMD using the company's experience in vector design and ophthalmology to expand into disease indications with larger markets.
Primary Exchange: NASDAQ
SIC Biological Products, (No Diagnostic Substances)
NAICS Biological Product (except Diagnostic) Manufacturing

AGTC is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
VXF Vanguard Extended Market ETF 6.8 B 6.8E+09 3,242 3242 0.0% 1E-05 79 K 78698
ITOT iShares Core S&P Total U.S. Stock Market ETF 18.6 B 1.85536E+10 3,550 3550 0.0% 0 27 K 26589
IWC iShares Microcap ETF 914.4 M 9.14374E+08 1,451 1451 0.02% 0.0002 162 K 162435

Wait, Before You Leave...